Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline trading services limited - albiglutide - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - eperzan on näidustatud ravi 2. tüüpi suhkurtõbi täiskasvanutel, et parandada glycaemic kontrolli, kui:monotherapywhen dieet ja füüsiline koormus üksi ei taga piisavat glycaemic kontrolli patsientidel, kellele kasutamine metformiin on ebasobivaks, kuna vastunäidustusi või talumatust. add-on kombinatsioon therapyin koos teiste glükoosi-langetavaid ravimeid, kaasa arvatud basaalrakuline insuliini, kui need koos dieedi ja füüsilise koormuse, ei taga piisavat glycaemic kontrolli (vt lõik 4. 4 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Eesti - eesti - Ravimiamet

viatris sia - trandolapriil - kõvakapsel - 2mg 98tk; 2mg 28tk; 2mg 50tk; 2mg 60tk; 2mg 100tk

Eesti - eesti - Ravimiamet

viatris sia - trandolapriil - kõvakapsel - 4mg 56tk; 4mg 98tk; 4mg 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolaktoon - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ja 5.